XT
AVTX icon

XTX Topco’s Avalo Therapeutics AVTX Stock Holding History

XTX Topco’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.89M Buy
126,732
+86,274
+213% +$1.35M 0.03% 876
2025
Q4 		$735K Buy
40,458
+26,508
+190% +$447K 0.02% 1273
2025
Q3 		$177K Buy
+13,950
New +$120K 0.01% 1888
2023
Q4 		– Sell
-77
Closed -$2.23K – 1585
2023
Q3 		$2.23K Buy
+77
New +$3.44K ﹤0.01% 1493
2022
Q1 		– Sell
-4
Closed -$20K – 673
2021
Q4 		$20K Buy
+4
New +$24K 0.01% 627

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

XTX Topco's AVTX Position: Q1 2026 in Review

XTX Topco increased its Avalo Therapeutics (AVTX) stake by 213% in Q1 2026, buying an estimated $1.35M and bringing the position to 126,732 shares worth $1.89M. The position accounts for 0.03% of the portfolio, ranked #876.

XTX Topco first reported a position in AVTX in Q4 2021 and has held it in 5 quarters since. 97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • XTX Topco held 126,732 shares of Avalo Therapeutics worth $1.89M as of Q1 2026.
  • XTX Topco bought 86,274 Avalo Therapeutics shares in Q1 2026, an estimated $1.35M.
  • Avalo Therapeutics made up 0.03% of XTX Topco's portfolio in Q1 2026, its #876 holding.
  • XTX Topco first reported a position in Avalo Therapeutics in Q4 2021 and has held it in 5 quarters since.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.